Home » Radioactive Drug Research Committee
Radioactive Drug Research Committee
Current RDRC Committee Roster
Vanderbilt Human Research Protection Program
Radioactive Drug Research Committee – Institutional Review Board
FDA Registration Number – RDRC013
The RDRC Committee meets the first Friday of every quarter at 10:00AM. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).
Effective – June 15, 2016
|VOTING MEMBERS (5)||SPECIALTY|
|Chair, Eric T. Shinohara, MD||Radiation Oncology|
|Vice-Chair, Gary Smith, MD||Nuclear Medicine|
|Mary Ann Keenan, DMP||Radiology and Radiological Sciences|
|Charles Manning, PhD||Molecular Imaging|
|David Pickens, Ph.D.||Radiology and Radiological Sciences|
|Bapsi Chakravarthy, M.D.||Radiation Oncology|
|Dominique Delbeke, M.D., Ph.D.||Nuclear Medicine|
|Marni Gardner, D.Ph.||Nuclear Pharmacist|
|Ron Price, PhD||Radiology and Radiological Sciences|
|James Patton, PhD||Radiology and Radiological Sciences|
Vanderbilt’s Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain “non-approved” radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.
For an application form, a list of radiation doses, or examples of risk statements, please go to the IRB Forms page.